Table 1.
Clinicopathologic characterization of patients with gastric adenocarcinoma treated by surgery in combination with chemotherapy
| Normal serum CEA (median 52 yr, range: 22-74 yr) | Elevated serum CEA (median 54 yr, range: 32-73 yr) | ||
| Data | n (%) | n (%) | P |
| Sex | 0.090 | ||
| Male | 116 (67.1) | 44 (80.0) | |
| Female | 57 (32.9) | 11 (20.0) | |
| Tumor location | 0.115 | ||
| Upper | 52 (30.0) | 26 (47.3) | |
| Middle | 42 (24.3) | 12 (21.8) | |
| Lower | 68 (39.3) | 15 (27.3) | |
| Total | 11 (6.4) | 2 (3.6) | |
| Histological grade | 0.128 | ||
| G1 | 1 (0.6) | 0 (0) | |
| G2 | 31 (17.9) | 18 (32.7) | |
| G3 | 112 (64.7) | 29 (52.7) | |
| G4 | 29 (16.8) | 8 (14.6) | |
| Tumor size | 0.053 | ||
| ≤ 2 cm | 23 (13.3) | 1 (1.8) | |
| 2 cm < diameter ≤ 5 cm | 98 (56.6) | 36 (65.5) | |
| > 5 cm | 52 (30.1) | 18 (32.7) | |
| Boarrman type | 0.093 | ||
| I | 3 (1.7) | 0 (0) | |
| II | 90 (52.0) | 20 (36.4) | |
| III | 69 (39.9) | 28 (50.9) | |
| IV | 11 (6.4) | 7 (12.7) | |
| Pathological T staging1 | 0.664 | ||
| T0 | 6 (3.5) | 1 (1.8) | |
| T3 | 156 (90.2) | 49 (89.1) | |
| T4 | 11 (6.4) | 5 (9.1) | |
| Lymph node metastasis rate | 0.951 | ||
| 0 | 12 (6.9) | 3 (5.5) | |
| 0 < r ≤ 0.1 | 29 (16.8) | 8 (14.5) | |
| 0.1 < r ≤ 0.3 | 50 (28.9) | 17 (30.9) | |
| r > 0.3 | 82 (47.4) | 27 (49.1) | |
| Surgery | 0.313 | ||
| Radical | 165 (95.4) | 50 (90.9) | |
| Palliative | 8 (4.6) | 5 (9.1) | |
| Chemotherapy | 0.384 | ||
| Adjuvant | 130 (75.1) | 38 (69.1) | |
| Perioperative | 43 (24.9) | 17 (30.9) |
1
Pathological T staging was based on the 6th Union for International Cancer Control’s staging systems for gastric cancer. CEA: Carcinoembryonic antigen.